Table 1.
Baseline characteristics of the three groups n (%)
| Variable | Tol group | CNI group | MMF group | P-value |
| Patients (n) | 10 | 21 | 15 | NS |
| Age (yr) al TX | 52.4 ± 5.5 | 54.7 ± 10.3 | 50.4 ± 5.7 | NS |
| Gender (M/F) | 8/2 | 17/4 | 11/4 | NS |
| BMI | 26 ± 3.9 | 27 ± 3.4 | 27 ± 2.9 | NS |
| Donor age (yr) | 35 ± 13 | 44 ± 17.9 | 33 ± 18 | NS |
| Follow-up from LT (mean) | 83 ± 30.5 | 83 ± 29.1 | 89 ± 40 | NS |
| HCV genotype 1-4 | 2 (20) | 6 (28.5) | 6 (40) | NS |
| HCV genotype 2-3 | 1 (10) | 3 (14.2) | 2 (13.3) | NS |
| HCV-RNA > 500000 IU/mL | 70 | 42.8 | 46.6 | NS |
| Anti-HBc positive recipients | None | 4 (19) | 1 (6.6) | NS |
| Cholestatic hepatitis | None | None | None | NS |
| HIV positive | None | None | None | NS |
| Azathioprine treated | 1 (10) | 7 (33.3) | 9 (60) | NS |
| Mean ALT (IU/L) | 71.1 ± 54.2 | 53.9 ± 33.7 | 59.4 ± 45.6 | NS |
| ACE-inhibitors treated | 3 (30) | None | 1 (6.6) | NS |
| IDDM | 3 (30) | 7 (33.3) | 4 (26.6) | NS |
| Baseline Fibrosis score (Ishak) | 2.7 ± 0.7 | 2.2 ± 1.7 | 2.5 ± 1.5 | NS |
| Baseline grading score (Ishak) | 4.1 ± 1.8 | 3 ± 2.2 | 3.2 ± 1.6 | NS |
| Treated with ribavirin | 8 (80) | 9 (42.8) | 7 (46.6) | NS |
| Patients who achieved SVR | 2 | 8 | 5 | NS |
| Rejection episode | None | None | None | NS |
| Boluses of steorids after LT | None | None | None | NS |
| Antibodies after LT | None | None | None | NS |
| CMV infection after LT | 1 (10) | 2 (9.5) | 1 (6.7) | NS |
| Total ishemica times (min) | 502 ± 133.8 | 456 ± 86.5 | 411 ± 127.6 | NS |
| Liver donor's steatosis | None 0 (20) Mild 2 (10) Severe 0 (0) | None 17 (81) Mild 3 (14.3) Severe 1 (4.8) | None 14 (93.3) Mild 1 (6.7) Severe 0 (0) |
HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; CNI: Calcineurin inhibitors; MMF: Mycophenolate; BMI: Body mass index; CMV: Cytomegalovirus; LT: Liver transplantation; SVR: Sustained virologic response; IDDM: Insulin dependent diabetes mellitus; NS: Not significant.